About this medicine

Food is important for absorption; taking the tablet without food can reduce the amount reaching the bloodstream.

What is this medicine used for?

The UK indication is schizophrenia from age 13. American indications must not be assumed to apply to Latuda in the UK.

Which warning signs need help?

Get urgent help for fever with muscle rigidity or reduced consciousness, severe allergy, or chest pain with breathlessness suggesting a clot.

How do I take it safely?

The labelled starting dose is 37 mg daily. Adult doses may reach 148 mg; ages 13–17 have a 74 mg maximum. Organ impairment or interactions require different limits.

Moderate or severe kidney impairment generally changes the starting dose to 18.5 mg and the maximum to 74 mg/day; severe liver impairment limits the maximum to 37 mg/day. Moderate CYP3A4 inhibitors also require a lower start and ceiling. These distinctions must be prescribed, not inferred from tablet size.

What side effects should I know about?

Reported effects include nausea, restlessness, insomnia, sleepiness and movement symptoms. Weight and metabolic changes remain possible.

Akathisia means an uncomfortable need to move, not simply anxiety. Persistent tongue or facial movements may represent tardive dyskinesia. Raised prolactin can affect periods, sexual function or breast symptoms; report these for review.

Who needs extra care with this medicine?

Discuss heart, kidney or liver disease, diabetes, seizures, Parkinson’s disease and dementia before treatment.

Can it affect my other medicines?

Strong CYP3A4 inhibitors and inducers are contraindicated. Avoid grapefruit; alcohol can worsen impairment. A pharmacist should check the complete medicine list.

Contraindicated examples include clarithromycin, ketoconazole, ritonavir, carbamazepine and St John’s wort. A medicine being available without prescription does not make it compatible.

What check-ups will I need?

Review symptoms, movement effects, weight, blood pressure, glucose and lipids. NICE also includes baseline prolactin and an ECG when indicated.

What about pregnancy, breastfeeding and age?

Pregnancy and breastfeeding need individual discussion. Late-pregnancy exposure may affect the newborn. The checked indication does not extend below age 13.

The SmPC describes limited pregnancy data and recommends use only when clearly necessary. It does not establish whether lurasidone enters human milk; breastfeeding requires explicit assessment. Antipsychotic-class mortality concerns in elderly people with dementia are not an indication to treat dementia with Latuda.

What if I miss a dose or want to stop?

For one missed dose, resume the next day without doubling. Contact the prescriber after two or more missed doses.

How does it work?

Lurasidone changes responses to dopamine and serotonin, chemical messengers used by brain cells. It blocks some receptors, the proteins that receive these messages, and partly activates another type. These actions may contribute to its benefits, but the full explanation of how symptoms improve remains uncertain.

How Brain Cells Communicate

Brain cells communicate by releasing chemical messengers called neurotransmitters. A receiving cell responds through receptors, and different types of receptor can respond differently to the same messenger. Dopamine and serotonin act in many connected networks, so a change at one receiving site is only part of a much larger pattern of brain activity.

What is known: Messages are received through particular types of receptor.

What remains uncertain: One receiving site cannot account for a whole mood episode or experiences such as hearing voices others cannot hear.

Dopamine: D2 receptor

A messenger acts at a solid membrane receptor; protein coupling inside the cell illustrates a signaling response, rather than passage through an ion pore. Dopamine: A messenger can change signaling through its receptor. D2 receptor: This receptor symbol identifies a function, not a molecular structure. Cell response: The arrow represents a signaling response, not movement through a pore.
  1. Dopamine

    A messenger can change signaling through its receptor.

  2. D2 receptor

    This receptor symbol identifies a function, not a molecular structure.

  3. Cell response

    The arrow represents a signaling response, not movement through a pore.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Dopamine can activate d2 receptor and change signaling in the cell.

Serotonin: 5-HT1A receptor

A messenger acts at a solid membrane receptor; protein coupling inside the cell illustrates a signaling response, rather than passage through an ion pore. Serotonin: A messenger can change signaling through its receptor. 5-HT1A receptor: This receptor symbol identifies a function, not a molecular structure. Cell response: The arrow represents a signaling response, not movement through a pore.
  1. Serotonin

    A messenger can change signaling through its receptor.

  2. 5-HT1A receptor

    This receptor symbol identifies a function, not a molecular structure.

  3. Cell response

    The arrow represents a signaling response, not movement through a pore.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Serotonin can activate 5-ht1a receptor and change signaling in the cell.

Messages are received through particular types of receptor. Simplified illustration of the process; individual responses vary.
About this illustration

Chemical messages. One receiving site cannot account for a whole mood episode or experiences such as hearing voices others cannot hear.

A receptor diagram cannot represent a whole mood episode or psychotic experience.

Qualitative teaching model

How the Medication Changes Signaling

Lurasidone blocks dopamine D2 receptors and serotonin 5-HT2A and 5-HT7 receptors; these labels identify receiving-site types, and 5-HT means serotonin. Blocking a receptor’s activation is called antagonism. At serotonin 5-HT1A receptors it has partial agonist activity, meaning it activates the receptor but produces a smaller response than a full activator under comparable conditions. Each action changes a different part of communication between cells.

What is known: Lurasidone blocks selected receptors and partly activates another serotonin receptor type.

What remains uncertain: Laboratory findings cannot tell us how much each action contributes to someone’s improvement.

Lurasidone: D2 receptor

A receptor with natural messenger and a separate terracotta medicine symbol above the membrane; intracellular proteins illustrate the downstream signaling context. Dopamine: A messenger can change signaling through its receptor. D2 receptor: This receptor symbol identifies a function, not a molecular structure. Lurasidone: activation opposed: The crossbar marks opposition to receptor activation, not permanent closure.
  1. Dopamine

    A messenger can change signaling through its receptor.

  2. D2 receptor

    This receptor symbol identifies a function, not a molecular structure.

  3. Lurasidone: activation opposed

    The crossbar marks opposition to receptor activation, not permanent closure.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Lurasidone antagonizes D2 receptors; the article also describes its serotonin antagonist actions. This panel is one target example.

Lurasidone: 5-HT1A receptor

A partial-agonist symbol near a receptor, with intracellular signaling proteins below. Their number is not an activation scale. Lurasidone: The oval identifies the medicine acting at the 5-HT1A receptor. It is a concept symbol, not a molecular shape or binding pose. 5-HT1A receptor: This receptor symbol identifies a function, not a molecular structure. Lurasidone: partial activation: A dashed arrow marks context-dependent partial activation; it is not a numerical effect scale.
  1. Lurasidone

    The oval identifies the medicine acting at the 5-HT1A receptor. It is a concept symbol, not a molecular shape or binding pose.

  2. 5-HT1A receptor

    This receptor symbol identifies a function, not a molecular structure.

  3. Lurasidone: partial activation

    A dashed arrow marks context-dependent partial activation; it is not a numerical effect scale.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Lurasidone partly activates 5-HT1A receptors. This action differs from its antagonism at D2, 5-HT2A and 5-HT7 receptors.

Lurasidone blocks selected receptors and partly activates another serotonin receptor type. Simplified illustration of the process; individual responses vary.
About this illustration

Lurasidone actions. Laboratory findings cannot tell us how much each action contributes to someone’s improvement.

Their separate contributions to treatment response cannot be inferred from affinity values alone.

Qualitative teaching model

A Closer Look at the Molecular Level

Laboratory studies show little binding to histamine H1 or muscarinic M1 receptors, receiving sites for two other chemical messengers, histamine and acetylcholine, respectively. This describes a binding profile, or pattern of targets, and does not guarantee freedom from sleepiness or other unwanted effects. Food affects how much lurasidone is absorbed, and CYP3A4, an enzyme that helps process medicines, is important in breaking it down. These factors affect exposure, meaning the amount of medicine present over time, without changing which molecule the person is taking.

What is known: Food and the body’s processing of lurasidone influence how much reaches the bloodstream.

What remains uncertain: A pattern of receptor binding cannot predict how well someone will feel on the medicine or how much it will help.

Binding and exposure

  • Receptor profile
  • Food / metabolism
Food and the body’s processing of lurasidone influence how much reaches the bloodstream. Simplified illustration of the process; individual responses vary.
About this illustration

Binding and exposure. A pattern of receptor binding cannot predict how well someone will feel on the medicine or how much it will help.

This diagram does not promise a side-effect-free treatment or predict individual benefit.

Qualitative teaching model

How does it affect my body?

Restlessness, sleepiness or dizziness can interfere with activities. Avoid driving when affected.

How does my body process it?

CYP3A4 is central to its metabolism, making some enzyme-inhibiting or enzyme-inducing medicines important interaction risks.

How do treatment options differ?

A shared antipsychotic class does not make doses or indications interchangeable. Latuda’s meal requirement matters when comparing treatment routines.

UK strength labels express lurasidone, whereas some international labels express its hydrochloride salt. Do not reinterpret 37 mg as a different prescription merely because another country labels the corresponding salt amount differently.

A closer look at the science

It also blocks 5-HT7 receptors and partially stimulates 5-HT1A receptors. These binding properties do not predict an individual response.

Latuda contains lurasidone hydrochloride, the hydrochloride salt of lurasidone. The organic parent and the chloride component should not be confused with a single neutral parent molecule.

Chemical formula: C28H36N4O2S · HCl

C, H, N, O and S identify carbon, hydrogen, nitrogen, oxygen and sulfur in the lurasidone component; HCl identifies the hydrochloride component. The formula is chemical identity, not a dose-conversion tool.

A single neutral-parent drawing would omit the salt component and can also obscure the specified stereochemistry. The product-specific structural formula is available in section 11 of the linked official label; no unverified or simplified chemical structure is substituted here.

How was this medicine developed?

The manufacturer’s currently listed UK SmPC checked for this record carries a July 2022 revision date; that is a document date.

Latuda first received US approval for schizophrenia in October 2010. That international milestone does not establish UK licensing; the UK product’s indications and strengths are checked separately here.

Sources and References

  1. Latuda 37 mg tablets — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  2. Latuda 18.5 mg, 37 mg and 74 mg tablets — UK patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  3. Psychosis and schizophrenia in adults: recommendations

    Scope: NICE guidance for England; application in other UK nations determined separately.

  4. Drugs@FDA: Latuda approval and regulatory history

    Scope: United States; historical approval only.

  5. Latuda: current US prescribing information (1/2025)

    Scope: Shared scientific explanation; source remains US, not UK prescribing authority.

  6. What Is a Neurotransmitter?

    Scope: Shared scientific explanation; source remains US, not UK prescribing authority.

  7. A qualitative investigation into the effects of akathisia - Health Research Authority
  8. Extrapyramidal side effects- Management
  9. Anxiety and panic attacks - NHS
  10. Agitation: MedlinePlus Medical Encyclopedia
  11. Tardive dyskinesia: MedlinePlus Medical Encyclopedia
  12. NIMH: Mental Health Medications

Shared scientific background. US product pharmacology and chemical references do not establish UK licences, doses, formulations or NHS recommendations.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top